Bayer AG NA

2021 Q2–Q3

Bayer posted an additional gross provision of USD 4.5 billion in Q2 2021 to reflect potential long-term Roundup exposure. The company announced measures to manage and resolve litigation, including withdrawal of glyphosate-based Roundup from the U.S. residential market starting in 2023. A federal judge rejected Bayer's proposed USD 2.0 billion deal for future Roundup claims in May 2021. [8], [10]

Investors treated litigation as the principal overhang. The provision and product withdrawal signalled a pragmatic, risk-management stance but left a large binary liability risk on the balance sheet. [8]

FY 2021 (reported early 2022)

Bayer reported operational recovery with Group sales of €44.08bn and core EPS of €6.51, supported by recovering free cash flow and improving net financial debt. [12], [17]

Market view became mixed: operational momentum from Crop Science strength supported a recovery narrative, but unresolved U.S. litigation continued to limit valuation multiples. [12]

June 2022

The U.S. Supreme Court declined to hear Bayer/Monsanto appeals in the Hardeman (June 21) and Pilliod (June 27) cases, leaving multimillion jury awards intact and preserving substantial litigation exposure. [21], [22], [24]

Investor sentiment soured as the path to quick legal finality narrowed and potential liability remained large and uncertain. [21]

FY 2022 (reported Feb 2023)

Bayer delivered a strong operational year with Group sales of €50.739bn and EBITDA before special items of €13.513bn. Crop Science posted record sales of approximately €25.17bn with materially higher EBITDA; core EPS rose to approximately €7.94. [33], [34], [39], [40]

Investors briefly re-rated Bayer toward an operational growth narrative driven by Crop Science outperformance, though litigation remained a looming downside tail. [33], [40]

Feb–Jun 2023 (governance reset)

Bayer announced Bill Anderson (ex-Roche pharma) as CEO, joining the Board April 1 and assuming the CEO role from June 1, 2023. Werner Baumann retired end-May 2023 after sustained investor pressure for leadership change. [47], [49], [52], [61]

Perception shifted toward a governance and strategy reset. Investors hoped an external CEO would accelerate restructuring, cost cuts and portfolio review, including possible divestments or break-up scenarios. [47], [48], [60]

H2 2023 – FY 2023 (reported 2024)

Crop Science earnings weakened, notably from lower glyphosate prices and volumes. Q3 2023 was reported below prior year with Crop Science EBITDA sharply lower. FY2023 Group sales fell to €47.637bn and EBITDA before special items to €11.706bn. [45], [37], [44]

Market optimism cooled. The 2022 strength was seen as partly cyclical, and investors refocused on margin resilience, structural fixes and whether management would pursue concrete portfolio moves. [45], [48], [60]

30 Sep 2025 (provisions baseline reported in 2026 disclosure)

Bayer/Monsanto reported litigation provisions and liabilities of €7.8bn (including €6.5bn for glyphosate) as of 30 Sep 2025, cited as the baseline ahead of further negotiations. [5]

Markets treated the reported provisions as material but finite. Valuation remained sensitive to whether a negotiated global solution would close the remaining exposure. [5]

17 Feb 2026

Monsanto announced a proposed U.S. nationwide class settlement to resolve current and future Roundup claims, funded by declining capped annual payments totalling up to USD 7.25bn over up to 21 years. Bayer said the deal would increase litigation provisions and liabilities to approximately €11.8bn (including approximately €9.6bn for glyphosate), subject to approvals and audit. [5]

Market reaction was cautiously positive. The proposal was seen as major progress toward de-risking the balance sheet, but investor conviction was tempered pending judicial approval and implementation details. [5]

17 Jun 2026

A U.S. federal judge remanded the proposed USD 7.25bn settlement back to the Missouri state court that had fast-tracked approval, declining federal oversight and reintroducing procedural uncertainty. [7]

The remand re-introduced near-term legal risk and procedural uncertainty. Investors re-priced the deal as non-final and resumed a cautious stance. [7]

11 Jul 2026 (current)

Bayer (BAYN.XETRA) share price stands at 50.12.

The market price reflects the trade-off between demonstrated operational earnings power (Crop Science peak in 2022) and cyclical headwinds plus margin pressure since 2023, paired with residual but narrowing multi-year litigation uncertainty (settlement negotiations and court reviews). [33], [45], [5], [7]

Near-term catalysts are final court approval or rejection of the proposed Roundup resolution and clear, tangible portfolio and strategic actions from management.